Shots: CRISPR to receive $900M up front with an additional $200M milestone upon the regulatory approval of CTX001. Vertex will responsible for the global development, manufacturing, and commercialization of CTX001 Vertex will be responsible for 60% of program costs and will receive 60% of profits from future sales of CTX001 globally, representing a 10% increase […]Read More
Shots: The agreement facilitates PlantForm’s collaborations in Brazil to provide affordable, effective cancer drugs to millions of Brazilians The 3yrs. research and development collaboration will culminate in protocols for P-I and P-III clinical trials. The companies will take biosimilar pembrolizumab to world markets, following the completion of clinical trials in Brazil Pembrolizumab is a biosimilar […]Read More
Shots: The US FDA provide feedback on the pivotal trial protocol and statistical analysis plan (SAP) for the development program of biosimilar insulin glargine candidate, which the company plan to launch in 2023 The US FDA has requested Lannett to submit a protocol for the pivotal trial for review before IND submission. Lannett plans to […]Read More
In an interview with PharmaShots, Tillman Gerngross, Ph.D., Co-Founder, and CEO of Adagio Therapeutics shed light on the pre-clinical data of ADG2 and how it works on SARS-CoV-2. Shots: ADG2 showed broad and potent neutralizing activity against SARS-CoV and two SARS-related coronaviruses currently known to be circulating in bat populations (WIV-1 and SHC014) The company […]Read More
Shots: The collaboration will merge Microsoft’s computational services, cloud and AI with UCB’s drug discovery and development capabilities The companies intend to discover and develop medicines for people living with severe diseases in immunology and neurology. The collaboration follows UCB and Microsoft’s collaboration around COVID-19 Microsoft will provide AI technology and applied scientists to work […]Read More
Shots: Evotec to receive milestones, royalties, and a founding equity stake in all Related Sciences assets developed under the collaboration Evotec and Related Sciences will jointly discover & develop a multitude of therapeutic approaches with IND filings over a multi-year period. The partnership will combine Related Sciences’ collaborative model and data-driven approach to identify biological […]Read More
Shots: CQC collaborates with Roche to design and implement noisy-intermediate-scale-quantum (NISQ) algorithms for early-stage drug discovery and development The collaboration will employ CQC’s quantum chemistry platform ‘EUMEN’, to augment the Roche’s AD research efforts The multi-year collaboration will combine the expertise of both CQC and Roche to advance the application of quantum computing to pharmaceutical […]Read More
Shots: ViGeneron to receive an up front and R&D funding for the mutually agreed workplan and will receive development, regulatory and commercial milestone payments along with royalties on sales of products arising from the collaborations ViGeneron will optimize and validate in vitro therapeutic candidates for undisclosed target to treat inherited eye disease while Biogen has […]Read More
Shots: The companies collaborated to evaluate ruxolitinib in combination with CK0804 in patients with MF and plan to initiate a P-Ib study. Incyte will fund the study while operationalized by Cellenkos Cellenkos to receive $20M as licensing fee, ~$294.5M as development, regulatory and commercialization milestones along with royalties on sales of therapies, if approved. Incyte […]Read More
Shots: Cullinan will receive $20M up front and is eligible to receive ~$211M in development, regulatory and sales-based milestone payments Cullinan is also eligible for high-single-digit to low-teen tiered royalties based on sales of CLN-081 in Greater China includes Hong Kong, Macau and Taiwan CLN-081 is an orally available, small-molecule, irreversible EGFR inhibitor, which is […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
